Aster DM Healthcare Limited

100%

oard of directors of Aster DM Healthcare (“Company” or “Aster”) at their meeting today approved the 100% sale of its GCC business (“GCC Business”) § GCC Business will be acquired by Alpha GCC Holdings Lim

INR13,540

ubai International Financial Centre (“Aster GCC”) at an Enterprise Value of US$1,651.2m (equal to INR13,540cr) § At the closing of the Transaction, Fajr Capital & its consortium members will own ~65% and a

65%

INR13,540cr) § At the closing of the Transaction, Fajr Capital & its consortium members will own ~65% and a Promoter entity1 will own the remaining ~35% stake in the GCC Business through Aster GCC T

35%

Fajr Capital & its consortium members will own ~65% and a Promoter entity1 will own the remaining ~35% stake in the GCC Business through Aster GCC Transaction Overview § Aster shareholders will con

INR10,666

nities and to keep as reserves. § Enterprise Value3 § Equity Value Pre- Ind AS 116 US$1,300.7m (INR10,666cr) US$1,001.8m (INR8,215cr) Post- Ind AS 116 US$ 1,651.2m (INR13,540cr) US$ 1,001.8m (INR 8,215

INR8,215

ves. § Enterprise Value3 § Equity Value Pre- Ind AS 116 US$1,300.7m (INR10,666cr) US$1,001.8m (INR8,215cr) Post- Ind AS 116 US$ 1,651.2m (INR13,540cr) US$ 1,001.8m (INR 8,215cr) Upfront consideration

INR 8,215

INR10,666cr) US$1,001.8m (INR8,215cr) Post- Ind AS 116 US$ 1,651.2m (INR13,540cr) US$ 1,001.8m (INR 8,215cr) Upfront consideration of US$ 903m5 and up to US$98.8m to be received subsequently6 Upfront co

INR 751 Crore

p to US$98.8m to be received subsequently6 § EBITDA4 FY23 § Multiple EV / EBITDA FY23 US$ 91.6m (INR 751 Crores) US$ 138.9m (INR 1,139 Crores) 14.2x 11.9x § Finalization of definitive financing documents §

INR 1,139 Crore

subsequently6 § EBITDA4 FY23 § Multiple EV / EBITDA FY23 US$ 91.6m (INR 751 Crores) US$ 138.9m (INR 1,139 Crores) 14.2x 11.9x § Finalization of definitive financing documents § Shareholder’s approval § Comple

14.2x

BITDA4 FY23 § Multiple EV / EBITDA FY23 US$ 91.6m (INR 751 Crores) US$ 138.9m (INR 1,139 Crores) 14.2x 11.9x § Finalization of definitive financing documents § Shareholder’s approval § Completion of c

11.9x

FY23 § Multiple EV / EBITDA FY23 US$ 91.6m (INR 751 Crores) US$ 138.9m (INR 1,139 Crores) 14.2x 11.9x § Finalization of definitive financing documents § Shareholder’s approval § Completion of certain

INR 82

n Details (GCC Business) Key Pending Approvals & Items Target Completion Date Note: 1USD = INR 82 FX rate has been used for all conversion (1) “Promoter entity” refers to Dr. Moopen Family Holding C

“2) EBITDA for purposes of this calculation is Pre-Ind AS 10 Our plan towards utilization of transaction proceeds As internal accruals are sufficient to fund our organic growth plans at Aster India, most of the transaction proceeds will be distributed as dividend to our shareholders - allowing significant returns for them – and the balance will allow us to pursue inorganic growth opportunities 1 2 3 4 Net Transaction Proceeds (i.e.”

Neuroscience

2

Note

1

Multispeciality

1

Cardiology

1

Aster Medcity

1

Aster Hospitals

1

Aster CMI

1

Investor Relations

1

Note

(1) Clinics include Diagnostics ; Pharmacies include optics (2) Pharmacies in India are operated by ARPPL under brand license from Aster DM 5 Post-Segregation Structure INDIA LISTED ENTITY GCC ENTITY Promoters 41.88% Public 58.12% Promoters 35% Fajr Consortium 65% Aster DM Healthcare Limited Aster GCC3 Hospitals Clinics Pharmacies1 Labs & PECs Hospitals Clinics2 Pharmacies2 Kerala Karnataka Maharashtra Telangana Andhra Pradesh UAE KSA Oman Qatar Bahrain Jordan § § § No change in shareholding in India listed entity due to segregation Promoters to maintain their ~42% stake in the India listed entity and will hold 35% stake in the GCC entity Details of Aster Shareholders and the buyer group on the following slides Pharmacies in India are operated by ARPPL under brand license from Aster DM (1) (2) Clinics include Diagnostics ; Pharmacies include optics (3) Held by an entity named Alpha GCC Holdings Limited 6 Strategic rationale behind segregation 1 4 Creating pure-play India operating enti

Aster Medcity

Multispeciality (Private Listed) Aster Medcity Multispeciality Hospital: South India 5 6 Economic Times Healthcare Awards Best Hospital Ranking 2023 Economic Times Healthcare Awards

Neuroscience

All India 3 Aster Medcity: (National) Urology & Nephrology 1 Economic Times Healthcare Awards The Worlds Best Hospitals 2023 Reader’s Digest Healthcare Awards Aster CMI: (South) Gaestroenterology Hepatology 1 Aster CMI in India 27 Aster Medcity in APAC 49

Aster CMI

Most Trusted Hospital (Bengaluru) Our strategic priorities towards driving future growth and improvement in profitability Increasing Occupancy Current occupancy levels provide meaningful headroom for revenue growth through sweating of assets Cost Improvement Initiatives To help improve EBITDA Margins Improving Specialty Mix Focusing more on niche specialties to drive better ARPOB Asset Light Expansion Low Capex model to achieve better returns Focus on Virtual Care Connecting patients through digital app for better reach Capital Expenditure Substantial brownfield and greenfield investments in pipeline Significant potential for growth through our key strategic initiatives 33 34 Key Financials India Financial Summary- Profitability Statement FY23 Particulars (In INR Cr) Revenue from Operations Material Consumption Doctors’ Cost Employee cost (excl. doctors) Other expenses EBITDA (excl. other income) Depreciation & Amortization Finance Cost Add: Other income PBT PAT Income Tax Non controll